Spondyloarthritis & psoriatic arthritis
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA)
Authors' conclusion
There is substantial burden and unmet need for improved therapies for Canadians with PsA.
Study context
- Population
- Canadian patients with psoriatic arthritis (PsA) who initiated advanced therapy between January 2010 and December 2019 (Rhumadata and International Psoriasis and Arthritis Research Team (IPART) registries)
- Participants
- 1,596 patients
- Exposure
- Ontario vs Western Canada vs Quebec vs Atlantic/East
- Outcome
- Proportion of patients failing to achieve MDA
- Follow-up
- Within 6 months
Methodological detailsmultiregion, observational, multiregistry (Rhumadata and IPART)
- Multiregion
- Observational
- Multiregistry (Rhumadata and IPART)
Main finding
As reported in the abstract
Failure to achieve MDA within 6 months of an advanced therapy
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Western Canada | Atlantic/East |
|---|---|---|
| Continuing functional impairment | 24% | 83.3% |
- Continuing functional impairment: range across regions, lowest in the West, highest in the Atlantic/East
Failure to achieve minimal disease activity (MDA) by treatment class (IL-17i vs TNFi) · within 6 months
- Failure to achieve MDA higher with IL-17i than TNFi in all regions except the Atlantic/East
Patient-reported pain · 6 months
- Proportion reporting pain across regions
- 73.2% to 78.6%
Original publication
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA). J Rheumatol. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →